Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503425-18-00

Acronym

NP41300

Enrollment

112

Registered

2023-07-27

Start date

2019-10-02

Completion date

Unknown

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026